Abstract:Expression of interleukin-23 receptor (IL-23R) and IL-17 in urinary bladder carcinoma (UBC) was investigated to explore the correlations with prognosis. IL-23/IL-17 axis significantly inhibited the development of inflammatory bowel disease. Thirty patients with UBC were enrolled in Zhengzhou Central Hospital Affiliated to Zhengzhou University from September 2013 to September 2014. Tumor tissue and adjacent healthy tissue were collected, and the levels of IL-23R and IL-17 mRNA were detected by RT-PCR. Thirty healthy people were also selected to serve as normal control group. Serum levels of IL-23R and IL-17 in serum of UBC patients and normal controls were detected by ELISA, and the correlations with clinical features of UBC were analyzed. Pearson's correlation analysis was used to analyze the correlation between IL-23R and IL-17 protein expression. Follow-up study was performed by phone or during patient's visit to out-patient department. Overall survival (OS) and disease-free survival (DFS) curves were plotted by Kaplan-Meier method to analyze the correlation between expression of IL-23R and IL-17 and survival time. ROC curve was used to detect the diagnostic values of IL-23R and IL-17 protein for UBC. Levels of IL-23R and IL-17 mRNA in UBC tissue were 3.26 and 2.65 times higher than those in adjacent tissue (P<0.05), and serum levels of IL-23R and IL-17 protein in UBC patients were significantly higher than those in normal control group. Protein expression levels of IL-23R and IL-17 were correlated with clinical stage and lymph node metastasis in UBC patients (P<0.05), and Cox hazard model showed that L-23R and IL-17 expression may be independent factors for UBC (P<0.05), and high expression levels of IL-23R and IL-17 significantly shortened the OS and DFS (P<0.05). Serum levels of IL-23R and IL-17 can be used to effectively diagnose clinical stage and lymph node metastasis of UBC patients, and the combined diagnosis has a higher sensitivity and specificity than the diagnosis using a single factor. These findings indicated that expression levels of IL-23R and IL-17 were increased in tumor tissue and serum of UBC patients, and the increased expression levels of IL-23R and IL-17 were correlated with poor prognosis. Detection of IL-23R and IL-17 levels has certain clinical significance in the diagnosis and prognosis of UBC.

Interleukin-10 Level in Serum and Urine in Patients with Bladder Carcinoma and Its Clinical Significance

Correlation of Interleukin-10-1082G/A Single Nucleotide Polymorphism to the Susceptibility of Bladder Cancer

Clinical Significance of Serological and Urological Levels of Bladder Cancer-Specific Antigen-1 (BLCA-1) in Bladder Cancer.

[Relationship Between Interleukin-10 Level in Ascites of Patients with Primary Ovarian Epithelial Carcinoma and Immune Defect in Peritoneal Cavity].

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

High Baseline Levels of Interleukin-8 in Leukocytes and Urine Predict Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients Receiving Bacillus Calmette–Guerin Therapy: A Long-Term Survival Analysis

Clinical significance of CXCL10 and CXCR3 expression in patients with bladder neoplasm

Expression and significances of interleukin-2 and interleukin-10 in colonic mucosa of colon cancer patients

Urinary interleukin-8 and pH changes after intravesical bacillus calmette-guerin therapy for superficial bladder cancer:processing and prognostic value

Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis.

Detection of Serum Interleukin-10 Levels in Nasopharyngeal Carcinoma

Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma

Prognostic value of determining serum CA125 and IL-10 levels in patients with advanced non-mall cell lung cancer

Clinical Significance Of Serum Igf-I And Vegf Level In Bladder Tumor

SERUM INTERLEUKIN-18 LEVEL AS A PROGNOSTIC MARKER IN PATIENTS WITH COLORECTAL CARCINOMA

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

Expression and clinical significance of bladder cancer specific nuclear matrix protein 4 in urine of patients with bladder cancer

[Expression and Clinical Signification of IL-10 and IL-17 in Endometrial Cancer].

Expression and Significance of Bladder Cancer Specific Nuclear Matrix Protein 4 and Cytokeratin 19 Fragment in Urine of Patients with Bladder Cancer

The Change and Value of Hyaluronic Acid in Serum and Urine of Bladder Carcinoma Patients

Clinical Significance of the Reduction of UT-B Expression in Urothelial Carcinoma of the Bladder